ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Predicting Risk of Cytomegalovirus with Viral-Antigen-Specific CD154+ T-cells after Liver or Intestine Transplantation

C. Ashokkumar, K. Soltys, M. Green, G. Mazariegos, G. Bond, K. Jones, A. Rzempoluch, M. Zaccagnini, P. Sethi, B. W. Higgs, R. Sindhi

Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA

Meeting: 2019 American Transplant Congress

Abstract number: B31

Keywords: Cytomeglovirus, Intestinal transplantation, Liver transplantation, T cells

Session Information

Date: Sunday, June 2, 2019

Session Name: Poster Session B: Biomarkers, Immune Monitoring and Outcomes

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Clinical Rejection-Risk Assessment with Allospecific CD154+T-Cytotoxic Memory Cells (CD154+TcM) After Pediatric Liver or Intestine Transplantation (LTx, ITx).
  • CMV-Specific CD154+T-Cells and CMV Disease Status After Liver Or Intestine Transplantation (LTx, ITx)

*Purpose: Cytomegalovirus (CMV)-specific T-cells express IFNγ, measure cell-mediated immunity to CMV and can guide the timing and duration of antiviral therapy. CMV-specific T-cells also co-express CD154, which can substitute for IFNγ and is induced rapidly, but needs clinical validation.

*Methods: CMV-specific CD154+T-cells and their memory (CD45RO+) and naïve (CD45RO-) CD4 and CD8 subsets were measured with flow cytometry after <6-hour stimulation of cross-sectional single peripheral blood leukocyte samples with pp65 CMV antigen. Samples were obtained from a) 28 healthy adults to establish reference range, b) from 142 liver (LT) or intestine transplant (IT) recipients with or without CMV infection. All cross-sectional samples were obtained within the one month period before or the two week period after CMV viral load testing. CMV infection status was based on the presence or absence of CMV viremia measured with polymerase chain reaction. Recipients were not excluded based on CMV seropositive or seronegative status or any type of donor-recipient CMV serologic mismatch. Logistic regression was used to identify threshold frequencies of CMV-specific CD154+T-cells which were associated with absence of CMV viremia.

*Results: In 28 healthy adults, mean (SD) frequency (%) of CMV-specific CD154+T-cells and their memory and naïve subsets was 5.0 (0.3), 5.4 (0.3) and 4.7 (0.3), respectively and showed similar trends for CD4 and CD8 subsets. The 142 recipients included 117 LT and 25 IT recipients. Median (range) age was 10.7 years (0.4-30) and male: female distribution was 65: 77. Samples were obtained at median 1140 (0-7556) days after LT or IT. Twenty five children developed CMV viremia (n=24) or CMV hepatitis (n=1) with median viral load of 2320 copies/ml (range 341-429426) and demonstrated significantly lower (mean+/-SEM) frequencies of CMV-specific CD154+T-cells, compared with 117 children without CMV viremia (1.6+/0.2% vs 4.2+/-0.3%, p=2.4E-11). In 129 of 142 samples, all of which were obtained after transplantation, the threshold frequency of 1.73% CMV-specific T-cells, if exceeded, predicted absence of CMV viremia with negative predictive value or NPV (95% confidence interval) of 92% (85-97%). Corresponding positive predictive value (PPV), specificity and sensitivity were 54% (34-72%), 88% (80%-93%) and 65% (43-84%). In 13 remaining samples, all of which were obtained before transplantation, CMV-specific T-cells of 1.73% or greater were seen in 8 of 11 children who were free of CMV viremia (specificity 73%). Both children with viremia demonstrated frequencies below this threshold (sensitivity 100%). The corresponding NPV was 100% and PPV was 40%.

*Conclusions: Transplant recipients at low risk for CMV viremia can be identified rapidly and with reasonable accuracy using CMV-specific T-cells, which express CD154 .

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ashokkumar C, Soltys K, Green M, Mazariegos G, Bond G, Jones K, Rzempoluch A, Zaccagnini M, Sethi P, Higgs BW, Sindhi R. Predicting Risk of Cytomegalovirus with Viral-Antigen-Specific CD154+ T-cells after Liver or Intestine Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/predicting-risk-of-cytomegalovirus-with-viral-antigen-specific-cd154-t-cells-after-liver-or-intestine-transplantation/. Accessed March 6, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.